Welcome to our dedicated page for Context Therapeutics news (Ticker: CNTX), a resource for investors and traders seeking the latest updates and insights on Context Therapeutics stock.
Context Therapeutics Inc. (Nasdaq: CNTX) is a Philadelphia-based biopharmaceutical company dedicated to advancing innovative medicines for solid tumors. The company's core mission is to develop novel therapies for hormone-responsive cancers, with a particular focus on female cancers such as breast, ovarian, and endometrial cancer.
Context Therapeutics’ leading clinical candidate is CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody designed to target and engage T-cells in attacking CLDN6-positive tumors. Preclinical studies have shown promising results, with CTIM-76 demonstrating a capability to induce complete tumor regressions across multiple dose levels. The company plans to enroll the first patient in a Phase 1 clinical trial in mid-2024.
In addition to CTIM-76, Context Therapeutics is working on other promising programs, including Apristor (onapristone XR), an investigational drug targeting progesterone receptor-positive (PR+) breast cancer. Up to 70% of breast cancers express progesterone receptors, making Apristor a potential treatment option for a significant number of patients.
In recent news, Context Therapeutics announced encouraging financial results for the first quarter of 2024, including gross proceeds of approximately $100 million from a private placement. These funds are expected to support the company's operations and research endeavors well into 2028. The U.S. Food and Drug Administration (FDA) has also recently cleared Context's Investigational New Drug (IND) application for CTIM-76, a crucial step toward initiating clinical trials.
Context Therapeutics has a strong pipeline and strategic partnerships, including collaborations with Integral Molecular, which supports the development of therapies targeting difficult protein targets. The company’s robust financial guidance and innovative approach position it for significant growth in the biopharmaceutical sector.
Context Therapeutics Inc. announced a $100 million private placement with healthcare investors to advance medicines for solid tumors. The financing will extend the cash runway into 2028. The private placement is expected to close on May 6, 2024, and includes the sale of approximately 64.5 million shares of common stock at $1.55 per share.
Context Therapeutics Inc. (NASDAQ:CNTX) is advancing therapies for solid tumors, focusing on Claudin 6 (CLDN6). The company is developing CTIM-76, a bispecific antibody targeting CLDN6, estimated to potentially treat 62,500 metastatic cancer patients in the U.S. CLDN6's unique presence in specific cancers, like ovarian and lung cancers, enables targeted T cell activation, minimizing damage to healthy cells. Context aims to address the limitations of current treatments, which can harm both cancerous and healthy cells, causing significant side effects. The company is set to present preclinical data at the AACR Annual Meeting on April 17 and plans to submit an IND filing by Q1 2024 for clinical trials. For more details, visit www.contexttherapeutics.com.
FAQ
What is the current stock price of Context Therapeutics (CNTX)?
What is the market cap of Context Therapeutics (CNTX)?
What does Context Therapeutics Inc. do?
What is CTIM-76?
What types of cancer is Context Therapeutics targeting with their therapies?
What recent milestones has Context Therapeutics achieved?
When does Context Therapeutics plan to start the Phase 1 trial for CTIM-76?
What are the financial prospects for Context Therapeutics?
Who are some of Context Therapeutics' strategic partners?
What regulatory approvals has Context Therapeutics received recently?
Where is Context Therapeutics headquartered?
What is Apristor?
